BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Astex Pharmaceuticals\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Astex Pharmaceuticals\, Inc.'s dr
 ugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04862663-7646@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Capivasertib: Phase 3 readout est. (NCT04862663)
DESCRIPTION:Capivasertib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER
 2- Breast Cancer (CAPItello-292)\nEstimated primary completion: 1 November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/capivasertib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04862
 663
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764186-7646@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Capivasertib: Phase 3 readout est. (NCT06764186)
DESCRIPTION:Capivasertib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combinatio
 n With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relaps
 ed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Pr
 actice in Spain\nEstimated primary completion: 30 November 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/capivasertib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06764186
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
